The Proclaimsm (Proleukin® Observational Study to Evaluate Treatment Patterns and Clinical Response in Malignancy) Study: The Response Rates for High Dose Interleukin-2 (HD IL-2) Therapy

被引：0
|
作者：
Kaufman, Howard [1 ]
McDermott, David [2 ]
Morse, Michael [3 ]
Lowder, James [4 ]
Wong, Michael [5 ]
机构：
[1] Rush Univ, Chicago, IL 60612 USA
[2] Harvard Univ, Boston, MA 02115 USA
[3] Duke Univ, Durham, NC USA
[4] Prometheus Labs Inc, San Diego, CA USA
[5] Univ So Calif, Los Angeles, CA USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2012年 / 35卷 / 09期
关键词：
Interleukin-2; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：749 / 750
页数：2
相关论文
共 50 条
  • [31] An international validation study of the interleukin-2 luciferase leukocyte toxicity test (IL-2 Luc LTT) to evaluate potential immunosuppressive chemicals and its performance after use with the interleukin-2 luciferase assay (IL-2 Luc assay)
    Yutaka, Kimura
    Rie, Yasuno
    Iwaki, Tomoko
    Fujimura, Chizu
    Ohmiya, Yoshihiro
    Nakajima, Yoshihiro
    Omori, Takashi
    Corsini, Emanuela
    Inoue, Tomoaki
    Rogen, Erwin L.
    Kojima, Hajime
    Aiba, Setsuya
    TOXICOLOGY IN VITRO, 2023, 88
  • [32] Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
    Sabatino, Marianna
    Kim-Schulze, Seunghee
    Panelli, Monica C.
    Stroncek, David
    Wang, Ena
    Taback, Bret
    Kim, Dae Won
    DeRaffele, Gail
    Pos, Zoltan
    Marincola, Francesco M.
    Kaufman, Howard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2645 - 2652
  • [33] Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease
    Asano, Takeru
    Matsuoka, Ken-Ichi
    Iyama, Satoshi
    Ohashi, Kazuteru
    Inamoto, Yoshihiro
    Ohwada, Chikako
    Murata, Makoto
    Satake, Atsushi
    Yoshida, Chikamasa
    Nakase, Koichi
    Mori, Yasuo
    Tanimoto, Mitsune
    ACTA MEDICA OKAYAMA, 2016, 70 (05) : 429 - 433
  • [34] Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era
    Clark, Joseph I.
    Wong, Michael K.
    Daniels, Gregory A.
    Kaufman, Howard L.
    McDermott, David F.
    Morse, Michael A.
    Aung, Sandra
    BJU INTERNATIONAL, 2014, 114 : 5 - 5
  • [35] Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
    Buchbinder, Elizabeth I.
    Dutcher, Janice P.
    Daniels, Gregory A.
    Curti, Brendan D.
    Patel, Sapna P.
    Holtan, Shernan G.
    Miletello, Gerald P.
    Fishman, Mayer N.
    Gonzalez, Rene
    Clark, Joseph I.
    Richart, John M.
    Lao, Christopher D.
    Tykodi, Scott S.
    Silk, Ann W.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [36] A Comprehensive Review of Low-Dose Interleukin-2 (IL-2) Therapy for Systemic Lupus Erythematosus: Mechanisms, Efficacy, and Clinical Applications
    Farooq, Amna
    Trehan, Shubam
    Singh, Gurjot
    Arora, Nirav
    Mehta, Tejal
    Jain, Prateek
    Bector, Gaurav
    Jain, Aayush
    Arora, Rajpreet S.
    Puri, Piyush
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (09)
  • [37] Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)
    Stenehjem, David D.
    Parikh, Kinjal
    Batten, Julia Anne
    Van Atta, Joan
    Crispin, Hilda
    Sageser, Daniel S.
    Grossmann, Kenneth F.
    Wang, Junfeng
    Tantravahi, Srinivas Kiran
    Samlowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [38] Correlation of tumor programmed death ligand-1 (PD-Ll) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in metastatic clear cell renal cell carcinoma (mccRCC).
    Gill, David
    Agarwal, Neeraj
    Stenehjem, David
    Agarwa, Archana F.
    Salama, Mohamad
    Merriman, Joseph
    Freeman, Gordon J.
    Choueiri, Toni K.
    Signoretti, Sabina
    BJU INTERNATIONAL, 2015, 116 : 8 - 9
  • [39] Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2
    Lindsey, KR
    Rosenberg, SA
    Sherry, RM
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) : 1954 - 1959
  • [40] Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2
    Weinreich, DM
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2002, 25 (02): : 185 - 187
12345